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Background: Primary IgA nephropathy (IgAN) is the most common form of idiopathic glomerulonephritis
worldwide. Although most patients are able to achieve remission with the current therapy, a large number of
patients will still progress to end-stage renal disease. This study aimed to evaluate kidney disease progression and
the risk factors for progression in IgAN patients who achieved remission.
Methods: Patients from a prospective database with IgAN were included in this study. All the subjects had
achieved a complete remission (CR) or partial remission (PR) following 6 months of therapy. Renal survival and the
relationship between the clinical parameters and composite renal outcomes were assessed.
Results: The study comprised 878 IgAN patients recruited between January 2005 and December 2010. Overall, 632
patients were enrolled in this study. The data from the 369 patients who achieved remission were analyzed; the
mean follow-up time was 49 months. The median serum creatinine (SCr) concentration at baseline was 91.3 μmol/L,
and the time-averaged creatinine (TA-SCr) was 91.8 μmol/L. The mean serum albumin (ALB) level at baseline was
39.4 g/L, and the time-averaged serum albumin (TA-ALB) was 42.1 g/L. Multivariate Cox regression analyses revealed
that the TA-ALB and TA-SCr levels were independently associated with the composite renal outcome. The patients with
a TA-SCr value > 120 μmol/L and a TA-ALB level < 38 g/L were less likely to recover from renal progression.
Conclusion: The strong predictive relationship of low TA-ALB and high TA-SCr levels with progression observed in this
study suggests that TA-ALB may serve as a marker of the long-term renal prognosis of IgAN patients who have
achieved remission.
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Primary IgA nephropathy (IgAN) is a very common idio-
pathic glomerulonephritis (GN) throughout the world
[1], especially in China, where IgAN accounts for 58.2%
of the GN cases [2]. Studies have confirmed that 1%-2%
of IgAN patients will develop end stage renal disease
(ESRD) within 1 year of diagnosis [3,4], and approxi-
mately 40% of patients will ultimately develop ESRD
within 20 years [5,6]. A wide variety of treatments have* Correspondence: shanmou_renji@126.com
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unless otherwise stated.been attempted to slow the progression of IgAN. Based
on the evidence, most treatment guidelines for IgAN
recommend optimal blood pressure control and suggest
adding steroids for those patients with persistent pro-
teinuria, regardless of supportive therapy [7]. However,
few studies have evaluated the progression of and risk
factors for the progression of IgAN under the current
treatment regimens.
Several clinical researchers [8-10] have confirmed the
prognostic value of certain clinical and biochemical pa-
rameters for the outcomes of patients with IgAN. Systolic
hypertension, massive proteinuria, renal impairment,
serum albumin (ALB) level [11,12], and severe histological
findings on a renal biopsy have been reported as riskThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinical course [5,14-18] are numerous and controversial
in the literature, including age at disease onset, gender,
obesity, hemoglobin levels, hypertriglyceridemia, inappro-
priate lifestyles, geography, and various immunogenetic
markers. One of the problems in the field is that previous
studies have consistently identified various clinicopatho-
logic parameters at the time of diagnosis, but the patients
were not followed long-term in most cases. By analyzing a
large number of patients, this study aimed to clarify the
long-term renal survival and related risk factors for pro-




The study comprised 878 IgAN patients recruited be-
tween January 2005 and December 2010 from the De-
partment of Nephrology, Ren Ji Hospital, Shanghai,
China. All the patients had definitive pathological data
with predominant (at least 1+) mesangial staining for IgA
according to immunofluorescence staining and electron-
dense deposits within the mesangium according to electron
microscopy analysis. Patients who presented at younger
than 18 years of age (n = 30), were pregnant (n = 3), had
acute kidney failure (n = 12), had less than 36 months of
follow-up (n = 160), had systemic inflammation such as
Henoch–Schönlein purpura (n = 6), or had chronic ad-
vanced liver disease (n = 35) were excluded. A total of 632
patients were included. The study was approved by the
Ethics Committee of Ren Ji Hospital, and all the partici-
pants gave written informed consent. All the kidney biopsy
slides were reviewed by an experienced renal pathologist.
Only those subjects in whom the treatment response
evaluated at 6 months after the initiation of therapy met
the criteria for a complete remission (CR) or partial remis-
sion (PR) were included in the present study. A CR was
defined as the absence of proteinuria, the normalization of
all biochemical findings, and a lack of worsening of renal
function. A PR was defined as a > 50% reduction in pro-
teinuria from baseline. No response (NR) was defined as
a < 50% reduction in proteinuria or an increase in protein-
uria, with or without renal deterioration. In the end, 369
patients who met the remission criteria were enrolled.
At the end of the follow-up, the estimated glomerular
filtration rate (eGFR) values were evaluated. The primary
outcome was a doubling of the baseline serum creatinine
(SCr); secondary outcomes included ESRD and death.
Patients were classified with progression when their
eGFR values decreased (below the normal range) ≥ 5 ml/
min/1.73 m2/year or reached the endpoint during the
follow-up period. The patients who stabilized or had a
slower decrease in the eGFR were considered as non-
progression patients. Among the 369 remission patients,61 were progression patients, and 308 subjects were
non-progression patients (Figure 1).
Clinical, biochemical and histopathological data collection
The patients had regular follow-up visits at intervals of at
least 3–6 months. All the data were collected prospectively.
The baseline clinical and demographic data were recorded
at the time of the renal biopsy. The demographic data in-
cluded age and gender. The clinical parameters included
systolic blood pressure (SBP), diastolic blood pressure
(DBP), blood erythrocytes (RBC), blood leukocytes (WBC),
thrombocytes (PLT), hemoglobin (Hb), SCr, serum uric acid
(UA), blood urea nitrogen (BUN), ALB, glutamic-pyruvic
transaminase (ALT), glutamic-oxaloacetic transaminase
(AST), triglyceride levels (TG), serum total cholesterol
levels (TC), high-density lipoprotein (HDL), low-density
lipoprotein (LDL), the erythrocyte sedimentation rate
(ESR), complement 3 (C3) levels, serum immunoglobulin
(IgA, IgG, IgM) levels, 24-h urinary protein excretion
(UPE), hematuria (uRBC/HP), and the eGFR at the diagno-
sis of IgAN and during the follow-up.
The eGFR was calculated using the Modification of Diet
in Renal Disease (MDRD) study equation: eGFR (ml/min/
1.73 m2) = 1.8 × [SCr (mg/dl)]-1.154 × (age)-0.203 × (0.742 if
female) [19]. Chronic kidney disease (CKD) was classified
based on the Kidney Disease Outcomes Quality Initiative
(K/DOQI) practice guidelines.
For each patient, proteinuria was measured via the UPE.
An average UPE was determined for each 3-month block
during the follow-up; the average of the UPE values for
every 3-month period was represented by the time-averaged
UPE (TA-UPE) [20]. The time-averaged serum albumin
(TA-ALB), time-averaged serum creatinine (TA-SCr), time-
averaged blood urea nitrogen (TA-BUN), and time-averaged
eGFR (TA-eGFR) values were calculated using the same
method as that used for the TA-UPE.
Most of the patients were treated according to the ac-
cepted standards at our center as follows: (1) full doses of
ACEis (angiotensin converting enzyme inhibitors) and/or
ARBs (angiotensin receptor blockers) were recommended
for all the patients with proteinuria or hypertension; (2)
steroids were used in cases of massive proteinuria (>1 g/
d); and (3) other immunosuppressive agents were consid-
ered in patients with impaired kidney function or rapidly
progressing kidney function decline (an increase in SCr >
15% in the year before entry into the trial) [21]. Renal le-
sions were graded according to the Lee’s classification at
the time the database was established [22].
Statistical analyses
Analyses of the data were carried out using SPSS software
(version 13: SPSS, Chicago, IL). For comparison of the con-
tinuous variables between the groups, Student’s t-test was
used if the variables had a normal distribution, and a
Figure 1 A flow diagram of the study. AKI: Acute kidney injury.
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distribution. The chi squared test was employed for the cat-
egorical variables. Cox’s proportional hazards models for
estimating the hazard ratios and the 95% confidence inter-
vals (CI) were used to identify the predictive factors for the
development of IgAN progression. The multivariate models
used a stepwise forward selection procedure based on a
likelihood-ratio test with P > 0.10 for the removal and P <
0.05 for the entry of the variables. Receiver operating char-
acteristic curves (ROC) were established to determine the
optimal cutoff value of a risk factor for predicting renal pro-
gression. In addition, ROC curves were also analyzed when
two risk factors were combined. Renal survival was esti-
mated with the Kaplan–Meier method, and comparisons
were performed using the log-rank test. The results were
reported as the means ± standard deviation (SD). Values of
P less than 0.05 were considered statistically significant.
Results
Baseline demographic and clinical data
From 2005 to 2010, 878 patients with primary IgAN
were recorded in the Registry Database, among whom246 cases were excluded and 632 cases were included in
this study. The data from a total of 369 patients with IgAN
who achieved remission 6 months following therapy were
utilized in the analyses. The clinical characteristics at base-
line and during the follow-up were summarized in Tables 1
and 2. All the subjects were Chinese. There were 184
males and 185 females in the study, and the mean age at
biopsy was 37.2 ± 12.3 years. The mean SBP and DBP at
baseline were 123.8 ± 15.9 mm Hg and 79.3 ± 9.5 mm Hg,
respectively. The mean eGFR was 83.6 ± 28.4 ml/min/
1.73 m2. The median and interquartile range (IQR) values
for the initial proteinuria were 2.1 and 1.2-3.2 g/d, respect-
ively. Moreover, 17% of the patients had ALB levels less
than 35 g/L, and the mean ALB level was 39.4 ± 5.5 g/L.
The patients were followed for 49.0 (38.0-65.8 months)
months, and 61 of these patients reached the endpoint of
the follow-up.
Comparison of the baseline characteristics of the
progression and non-progression groups
We compared the baseline characteristics of the progression
and non-progression groups (Table 1). Our data revealed
Table 1 Baseline clinical characteristics and renal parameters of patients with IgAN
Characteristics Remission patients Non-progression patients Progression patients P-value
(n = 369) (n = 308) (n = 61)
Age (years) 37.2 ± 12.3 37.0 ± 1.7 38.1 ± 3.9 NS
Gender: Female n (%) 185 (50.1) 160 (51.9) 25 (40.9) NS
SBP (mm Hg) 123.8 ± 15.9 123.5 ± 2.3 125.0 ± 3.7 NS
DBP (mm Hg) 79.3 ± 9.5 79.2 ± 1.4 79.8 ± 2.8 NS
RBC (X 1012/L) 4.4 ± 0.5 4.4 ± 0.2 4.5 ± 0.3 NS
WBC (X 109/L) 7.2 ± 1.7 7.0 ± 0.3 7.8 ± 0.4 NS
Hb g/L 133.7 ± 18.8 134.3 ± 2.9 131.3 ± 5.4 NS
PLT (X 109/L) 209.7 ± 63.8 215.5 ± 10.8 191.6 ± 23.6 NS
ALB g/L 39.4 ± 5.5 39.9 ± 0.8 37.7 ± 1.5 NS
ALT IU/L 16.0 (12.0-20.5) 16.0 (13.0-22.0) 15.0 (11.0-19.0) NS
AST U/L 19.7 ± 8.5 20.4 ± 1.7 17.5 ± 0.9 NS
TG mmol/L 1.6 (1.1-2.3) 1.56 (1.1-2.4) 1.9 (1.3-2.2) NS
TC mmol/L 5.0 (4.3-6.0) 4.97 (4.3-6.0) 5.1 (4.5-5.9) NS
HDL mmol/L 1.29 ± 0.5 1.3 ± 0.1 1.2 ± 0.1 NS
LDL mmol/L 3.35 ± 1.7 3.4 ± 0.3 3.1 ± 0.2 NS
FBG mmol/L 4.9 ± 0.5 4.93 ± 0.1 4.8 ± 0.2 NS
SCr μmol/L 91.3 ± 36.4 86.2 ± 4.7 112.8 ± 11.9 0.02
BUN mmol/L 6.1 ± 2.4 5.8 ± 0.3 7.7 ± 0.9 0.03
eGFR (ml/min/1.73 m2) 83.6 ± 28.4 87.7 ± 3.9 66.7 ± 7.8 0.03
UA μmol/L 337.0 (280.9-426.5) 327.5 (277.4-414.0) 370.0 (326.5-514.5) NS
Ca mmol/L 2.3 ± 0.1 2.3 ± 0.02 2.3 ± 0.1 NS
P mmol/L 1.2 ± 0.2 1.23 ± 0.05 1.2 ± 0.04 NS
ESR mm/h 22.0 (10.0-34.0) 22.0 (9.0-34.0) 24.0 (11.0-33.0) NS
IgA g/L 2.9 ± 0.9 2.8 ± 0.2 3.1 ± 0.2 NS
IgG g/L 12.3 ± 3.2 12.7 ± 0.6 11.4 ± 0.9 NS
IgM g/L 1.3 ± 0.8 1.4 ± 0.2 1.1 ± 0.2 NS
C3 g/L 1.05 ± 0.2 1.06 ± 0.04 1.0 ± 0.1 NS
UPE (g/d) 2.1 (1.2-3.2) 1.8 (1.2-3.1) 2.4 (2.0-3.6) NS
uRBC /HP 28.4 (7.5-50.0) 29.1 (7.2-50.0) 14.0 (9.4-29.1) NS
CKD stage n (%)
Stage 1 310 (84.0) 264 (85.7) 46 (75.4)
Stage 2 37 (10.0) 29 (9.4) 8 (13.1)
Stage 3 22 (6.0) 15 (4.9) 7 (11.5)
Stage 4 0 0 0
Stage 5 0 0 0 NS
Renal biopsy Lee’s classification n (%)
Grade I-II 13 (3.5) 13 (4.2) 0
Grade III 194 (52.6) 163 (52.9) 31 (50.8)
Grade IV 131 (35.5) 107 (34.7) 24 (39.3)
Grade V 31 (8.4) 25 (8.2) 6 (9.9) NS
Values are given as the means ± standard deviation (SD) if the variables showed a normal distribution and as medians (IQR) if the variables did not show a normal
distribution; n (%) was used for the categorical variables.
SBP: systolic blood pressure; DBP: diastolic blood pressure; RBC: blood erythrocytes; WBC: blood leukocytes; Hb: hemoglobin; PLT: thrombocytes; ALB: serum
albumin; ALT: glutamic-pyruvic transaminase; AST: glutamic-oxaloacetic transaminase; TG: triglyceride levels; TC: Serum total cholesterol levels; HDL: high density
lipoprotein; LDL: low density lipoprotein; FBG: fasting blood glucose; SCr: serum creatinine; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate;
UA: serum uric acid; Ca: serum calcium levels; P: serum inorganic phosphorus levels; ESR: erythrocyte sedimentation rate; IgA, IgG, IgM: serum immunoglobulin
levels; C3: complement 3 levels; UPE: 24-h urinary protein excretion; uRBC/HP: hematuria.
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Table 2 Comparison of characteristics between progression and non-progression patients during the follow-up
Characteristics Remission patients Non-progression patients Progression patients P-value
(n = 369) (n = 308) (n = 61)
ALB g/L at month 3 40.9 ± 4.9 41.3 ± 0.6 39.0 ± 1.7 NS
ALB g/L at month 6 42.9 ± 4.2 43.5 ± 0.6 40.5 ± 1.3 0.02
TA-ALB g/L 42.1 ± 3.8 42.7 ± 0.5 39.4 ± 1.2 0.01
SCr μmol/L at month 3 90.2 ± 35.5 82.7 ± 3.9 121.6 ± 13.9 0.01
SCr μmol/L at month 6 88.2 ± 37.5 80.3 ± 4.2 121.3 ± 14.1 0.002
TA-SCr μmol/L 91.8 ± 46.8 80.5 ± 4.2 136.7 ± 21.0 0.002
BUN mmol/L at month 3 7.4 ± 2.9 6.8 ± 0.3 9.8 ± 1.1 0.01
BUN mmol/L at month 6 6.5 ± 2.3 6.1 ± 0.3 8.0 ± 0.9 0.02
TA-BUN mmol/L 6.6 ± 2.2 6.1 ± 0.2 8.6 ± 0.9 0.004
eGFR (ml/min/1.73 m2) at month 3 85.5 ± 33.1 90.8 ± 4.4 63.4 ± 8.2 0.01
eGFR (ml/min/1.73 m2) at month 6 88.9 ± 33.7 95.1 ± 4.6 63.1 ± 7.8 0.003
TA-eGFR (ml/min/1.73 m2) 88.5 ± 33.2 95.1 ± 4.5 61.9 ± 8.1 0.002
UPE (g/d) at month 3 0.7 (0.4-1.3) 0.6 (0.2-1.0) 1.3 (0.7-2.0) 0.04
UPE (g/d) at month 6 0.4 (0.2-0.7) 0.4 (0.1-0.7) 0.4 (0.2-1.2) NS
TA-UPE (g/d) 1.1 (0.6-1.6) 1.0 (0.6-1.4) 1.3 (1.0-2.1) NS
Values are given as means ± standard deviation (SD) if the variables had a normal distribution and as medians (IQR) if the variables did not have a normal
distribution; n (%) was used for the categorical variables.
TA-ALB: time-averaged serum albumin; TA-SCr: time-averaged serum creatinine; TA-BUN: time-averaged blood urea nitrogen; TA-eGFR: time-averaged eGFR; TA-
UPE: time-averaged 24-h urinary protein excretion.
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renal function, as represented by the eGFR (66.7 ± 7.8 ml/
min/1.73 m2 versus 87.7 ± 3.9 ml/min/1.73 m2; P = 0.03),
the SCr level (112.8 ± 11.9 μmol/L versus 86.2 ± 4.7 μmol/L;
P = 0.02), and the BUN (7.7 ± 0.9 mmol/L versus 5.8 ±
0.3 mmol/L; P = 0.03). There were no significant differ-
ences in the other baseline characteristics, including
gender, age, blood pressure, ALB levels, and so on. The
classifications of the renal histopathology were summa-
rized in Table 1, and no significant differences were seen
between the progression and non-progression groups.
Comparison of the characteristics of the progression and
non-progression groups during the follow-up
The clinical profiles present during the follow-up after diag-
nosis were shown in Table 2. The renal function, as repre-
sented by the eGFR, SCr and BUN values, was significantly
different between the two groups, similar to what was ob-
served at baseline. The level of ALB at 6 months was lower
(40.5 ± 1.3 versus 43.5 ± 0.6 g/L; P = 0.02) in patients in the
renal progression group than those in the non-progression
group. The median value of the UPE at 3 months after the
initial biopsy was higher [1.3 (0.7-2.0) g/d versus 0.6 (0.2-
1.0) g/d; P = 0.04] in the progression group than in the
non-progression group. No significant difference was found
in the TA-UPE between the two groups.
The time-averaged characteristics of the two groups were
also summarized in Table 2, which indicated that the pro-
gressing patients had a lower level of TA-ALB (39.4 ± 1.2 g/L versus 42.7 ± 0.5 g/L; P = 0.01), a lower level of TA-eGFR
(61.9 ± 8.1 ml/min/1.73 m2 versus 95.1 ± 4.5 ml/min/
1.73 m2; P = 0.002), a higher level of TA-SCr (136.7 ±
21.0 μmol/L versus 80.5 ± 4.2 μmol/L; P = 0.002), and a
higher level of TA-BUN (8.6 ± 0.9 mmol/L versus 6.1 ±
0.2 mmol/L; P = 0.004) than the non-progressing patients.
Predictors of progression in IgAN patients who achieved
remission
Both univariate and multivariate Cox analyses were per-
formed to evaluate the impact of the potential predictors
of renal progression. As shown in Table 3, in the univari-
ate analyses, the SCr, BUN, and eGFR values at the base-
line and follow-up time periods, the ALB level at the
sixth month, and the TA-ALB were statistically signifi-
cant. Those factors that were significantly correlated
with progression on the basis of the univariate analysis
were further evaluated with a multivariate analysis. The
results revealed that only the TA-ALB and TA-SCr levels
were independently associated with renal progression.
The adjusted multivariate Cox analysis model indicated
that each 1 g/L drop in the TA-ALB level was associated
with a 14% increase in the risk of renal progression.
As mentioned previously, the TA-ALB value was used
to quantify the level of ALB during the follow-up of pa-
tients with IgAN, and the ROC curves for the TA-ALB
were established to determine the optimal cutoff values
for predicting a worse outcome (Table 4). The area
under the ROC curve (AUC) was 0.82 when the TA-
Table 3 Factors that were found to affect the long-term prognosis in IgAN patients in the univariate and multivariate
COX regression analyses
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
ALB g/L at month 6 0.86 0.76-0.96 0.01 NS
TA-ALB g/L 0.8 0.70-0.93 0.002 0.86 0.75-0.98 0.03
Baseline SCr μmol/L 1.02 1.01-1.04 0.003 NS
SCr μmol/L at month 3 1.03 1.02-1.05 <0.001 NS
SCr μmol/L at month 6 1.03 1.02-1.04 <0.001 NS
TA-SCr μmol/L 1.02 1.01-1.03 <0.001 1.02 1.01-1.03 <0.001
Baseline BUN mmol/L 1.37 1.14-1.65 0.001 NS
BUN mmol/L at month 3 1.35 1.15-1.59 <0.001 NS
BUN mmol/L at month 6 1.36 1.10-1.69 0.005 NS
TA-BUN mmol/L 1.56 1.25-1.94 <0.001 NS
Baseline eGFR (ml/min/1.73 m2) 0.97 0.94-0.99 0.01 NS
eGFR (ml/min/1.73 m2) at month 3 0.96 0.94-0.98 0.004 NS
eGFR (ml/min/1.73 m2) at month 6 0.96 0.93-0.98 0.001 NS
TA-eGFR (ml/min/1.73 m2) 0.96 0.93-0.98 0.001 NS
UPE (g/d) at month 3 1 1.00-1.002 0.003 NS
TA-UPE (g/d) 1 1.000-1.002 0.01 NS
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third month and at the sixth month, indicating that the
TA-ALB had a high diagnostic accuracy for an unfavor-
able renal outcome (sensitivity 90%, specificity 83%).
Based on the Kaplan-Meier analyses, the actual renal
survival according to the estimated 36-month risk was
plotted in Figures 2 and 3. The optimal cutoff for TA-
ALB was 38 g/L, indicating that the relationship be-
tween the TA-ALB values and renal outcomes was
dramatically altered at levels as low as 38 g/L. Those
with SCr levels > 120 μmol/L at baseline, the third
month, and the sixth month and ALB levels < 39 g/L at
the sixth month had an actual cumulative incidence of
reaching the primary endpoint.Table 4 Diagnostic performance of ALB for the identification
Characteristic Area under thecurve (AUC) 95% C
One characteristic
ALB at month 6 0.72 0.55-0.8
TA-ALB 0.76 0.59-0.9
Two characteristics combined
Baseline ALB combined with TA-ALB 0.77 0.62-0.9
ALB at month 3 combined with TA-ALB 0.82 0.65-1.0
ALB at month 6 combined with TA- ALB 0.77 0.60-0.9
Four characteristics combined
Baseline ALB combined with ALB at month
3, ALB at month 6, and TA-ALB
0.83 0.68-0.9Discussion
IgAN is a progressive disease that is characterized by
highly variable clinical courses and outcomes [3,23-25].
Although numerous long-term renal survival analyses of
patients with IgAN have been published [4,5,16,26,27],
few studies have calculated the long-term renal outcomes
of Chinese patients, especially those patients who achieve
remission after treatment. Nearly all of the patients re-
ceived RAS inhibitors. Steroids were considered in pa-
tients with UPE > 1 g/d, and other immunosuppressive
agents were considered in patients with rapidly progres-
sing renal function decline. Proteinuria declined by ap-
proximately 50%, and blood pressure was well controlled
among the patients treated with our current therapyof IgAN progression according to the ROC curve
I of AUC P value Cut-off value Sensitivity Specificity
9 0.02 41.35 0.75 0.74
3 0.01 40.89 0.8 0.7
3 0.01 0.8 0.74
0 0.001 0.9 0.8
4 0.01 0.8 0.67
6 0.001 0.9 0.83
Figure 2 Kaplan–Meier plots of the renal progression-free rates according to the ALB levels during the long-term follow-up. (A) ALB
levels at month 6, (B) TA-ALB levels. Patients with a ALB level at month 6 of < 39 g/L or TA-ALB < 38 g/L had significantly shorter progression-free
times (P < 0.05).
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more than 360 patients, we evaluated renal progression
and the risk factors for renal progression with the
current therapy regimen.
Although proteinuria is a known risk factor for the pro-
gression of IgAN [13,20,28,29], many important questionsFigure 3 Kaplan–Meier plots of renal progression-free rates according
SCr levels; (B) SCr levels at month 3; (C) SCr levels at month 6; (D) TA-SCr l
month 3, SCr > 120 μmol/L at month 6, or TA-SCr > 120 μmol/L had significregarding the role of proteinuria in the prognosis of IgAN
remain. In particular, the timing of the measurements re-
quires clarification. Some studies have proven that UPE at
diagnosis is often not a predictor of the outcome accord-
ing to a Cox regression analysis [25,26]; instead, UPE at
1 year or later may better indicate the prognosis [26]. Into the SCr levels at diagnosis and during follow-up. (A) Baseline
evels. Patients with baseline SCr > 120 μmol/, SCr > 120 μmol/L at
antly reduced progression-free times (P < 0.05).
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mild proteinuria (2 g/d); more than 70% of the patients
had proteinuria < 1 g/d. After a multivariate Cox analysis,
we were unable to provide clear evidence that the baseline
UPE was associated with renal outcomes. However, we
used the TA-UPE value to represent the average level of
proteinuria during the follow-up and demonstrated that,
while the TA-UPE was a strong predictor of renal function
decline in patients with IgAN according to the univariate
analysis, this parameter did not independently contribute
to the risk in the multivariate models.
At the time of the renal biopsy, a higher level of SCr
constituted an independent risk factor for long-term renal
survival. Similar to prior reports [2,4,5,8-10,16,26,27], we
confirmed that the baseline SCr and eGFR were associated
with renal progression among IgAN patients. We also
found that the levels of SCr and the eGFR during follow-
up were significantly different between the progression
and non-progression patients. The TA-SCr value was an
important independent risk factor for renal progression.
These clinical parameters are among the most consistently
reported predictors of progression, with similar findings
observed across multiple cohorts [2,4,5,8-10,16,26,27].
Apart from the traditional risk factors, the ALB level
during the follow-up was identified as a novel predictor
for the progression of IgAN in this study. The adjusted
multivariate Cox analysis model revealed that each 1 g/L
drop in the TA-ALB level was associated with a 14% in-
crease in the risk of renal progression. The ROC curve in-
dicated that the combination of the ALB at baseline and
at follow-up has a more significant value in the prediction
of renal outcome. According to the Kaplan-Meier analysis,
we found that the patients with a TA-ALB < 38 g/L had a
10.4-fold increased risk of progression compared with
those with a TA-ALB > 38 g/L. These results demonstrate
that patients are expected to have more unfavorable out-
comes when the ALB level during follow-up is reduced
to < 38 g/L. Therefore, we speculate that the optimal goal
for TA-ALB among Chinese patients with IgAN should
be > 38 g/L.
The ALB level is widely recognized as a biomarker of
nutritional status and inflammation [30]. Hypoproteine-
mia is a common complication of CKD that has recently
emerged as an important independent risk factor for
kidney disease progression [2,31-36]. To our knowledge,
our study is the first to identify ALB during a long-term
follow-up as an independent risk factor for renal out-
comes in IgAN patients. In a study based on a Chinese
population, Chen N et al. [9] demonstrated an independ-
ent association of low baseline ALB levels with disease
progression among patients with IgAN. Liu ZH et al. [2]
found that baseline hypoproteinemia was an independ-
ent risk factor for an unfavorable IgAN outcome. In con-
trast to these studies, we did not find a relationshipbetween baseline ALB and renal progression. Instead,
our study provides strong support for the predictive
value of ALB during a long-term follow-up for the as-
sessment of renal progression risk. In this study, we used
TA-ALB values to represent the average level of ALB
during the follow-up and demonstrated that the TA-
ALB value was a strong predictor of renal progression in
patients with IgAN.
In addition, our findings did not confirm any independ-
ent association of blood pressure or pathological grading
with renal survival. This finding is partly due to the fact
that most patients had a normal arterial pressure level
after the administration of anti-hypertensive agents, such
as full doses of ACEis and/or ARBs. Furthermore, our
study applied Lee’s pathological classifications, which
might have a limited predictive capacity compared with
the Oxford classifications. The Oxford classification sys-
tem is based upon four scores (mesangial hypercellularity,
segmental glomerulosclerosis, endocapillary hypercellular-
ity, and tubular atrophy/interstitial fibrosis) and consti-
tutes an effective method for predicting renal outcomes
[37,38].
This study is unique in that it identified predictors for
clinical outcomes among a pool of IgAN patients who
achieved either a CR or a PR. In addition, this IgAN
study also has a relatively longer follow-up time, involv-
ing more than 360 patients followed for 100 months.
The strengths of this study include the large number of
IgAN patients, a uniform therapy strategy, and the ro-
bust database, for which all the data were collected at
regular 3-month intervals. However, the results of this
study are limited by its location at a single medical cen-
ter, and most of the patients recruited came from the
southern regions of China. Furthermore, the renal func-
tion of most of the patients at the beginning of the trial
period was good, and approximately 94% of the patients
were in CKD stage 1–2. Therefore, the analyses had an
inherent selection bias for disease severity and treatment
choice. Thus, more studies are required to evaluate the
progression of IgAN in patients under the current treat-
ment regimen in the future.
Conclusion
In summary, our data clearly showed that the TA-SCr and
TA-ALB levels were associated with renal outcomes in pa-
tients achieving remission under the current therapeutic
regimens for IgAN. Furthermore, ALB, especially during
the follow-up, is a potential predictor for IgAN prognostic
outcomes.
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